Rafael Dariolli

Rafael Dariolli is CEO of Bonds Biosystems, a platform company turning human organoids into decision-grade in vitro data for metabolic disease and cardiotoxicity screening. He spent more than a decade at the Heart Institute (InCor) of the University of São Paulo, one of Latin America's leading cardiology centers, followed by 5+ years as Senior Scientist at the Icahn School of Medicine at Mount Sinai (Department of Pharmacological Sciences and Cardiovascular Research Institute). Previously Director of Pre-Clinical Therapeutics at LizarBio, he has worked on cardiac cell therapy for myocardial infarction since his master's research.